Evidence map›Paper›PMID 36367749›Full record

ArticleJournal of medicinal chemistry2022

Structure-Activity Studies of 1

Lucas B Fallot, R Rama Suresh, Courtney L Fisher, Veronica Salmaso, Robert D O'Connor, Noy Kaufman, Zhan-Guo Gao, John A Auchampach, Kenneth A Jacobson

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. From empirical screening to lipid trolling: the evolution of extrahelical allosteric modulators of AMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Bitopic AJournal of medicinal chemistry · 2025
    Article
  3. Review
  4. Article
  5. Lipid Trolling to Optimize AJournal of medicinal chemistry · 2024
    Article
  6. Extrahelical Binding Site for a 1Molecular pharmacology · 2024
    Article
  7. Species dependence of APurinergic signalling · 2023
    Review
  8. Review
  9. AInternational review of neurobiology · 2023
    Article
  10. Characterization of Dual-Acting AACS pharmacology & translational science · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lucas B FallotMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.ORCID 0000-0003-3056-2947
R Rama SureshMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.ORCID 0000-0001-7693-3681
Courtney L Fisher
Veronica SalmasoMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.
Robert D O'ConnorMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.
Noy KaufmanMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.
Zhan-Guo GaoMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.
John A AuchampachORCID 0000-0002-8005-4599
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.ORCID 0000-0001-8104-1493

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Adenosine Signaling During Post-Infarction Remodeling and Heart FailureR01HL133589 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI AUCHAMPACH, JOHN A · 2017 to 2020
$1.7M
Drugs that Act at Adenosine ReceptorsZ01DK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$854k
Discovery of Adenosine Receptor Allosteric Modulators for Cardiovascular Disease and InflammationF31HL160193 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI FISHER, COURTNEY L · 2022 to 2022
$40k
Intramural NIH HHS Z01 DK031117Intramural NIH HHS ZIA DK031117NHLBI NIH HHS F31 HL160193NHLBI NIH HHS R01 HL133589NIMH NIH HHS HHSN271200800025C
6 · The paper itself

Abstract

We previously reported 1

Indexed as

Adenosine A3 Receptor AgonistsReceptors, Purinergic P1Allosteric RegulationAminesAnimalsCaco-2 CellsHumansRatsAdenosine A3 Receptor AgonistsAminesReceptors, Purinergic P1

Identifiers

PMID36367749
PMCPMC10354740

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.